Skip to main content

NCT00237302 - A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Migraine in Pediatric Subjects

A Comparison of the Efficacy and Safety of Topiramate Versus Placebo for the Prophylaxis of Migraine in Pediatric Subjects


Primary Citation

Not Available


Data Specification

Not Available


Annotated CRF

Available upon data request approval

Product Info

Generic Name
Topiramate
Product Name
TOPAMAX®
Therapeutic Area
Nervous System Diseases
Enrollment
162
% Female
48.4%
% White
77.1%
Product Class
Anticonvulsants
Sponsor Protocol Number
CAPSS-122
Data Partner
Johnson & Johnson
Condition Studied
Migraine Disorders
Mean/Median Age (Years)
11.1

Supporting Documentation

Clinical Study Report
Collected Datasets
Annotated Case Report Form
Protocol with Amendments
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.